Encouragingly, statins may counteract CAR-T resistance mechanisms that lead to metabolic reprogramming, underscoring that they still have unexhausted potential for TP53 mutant AML that warrants further investigation [209]. The gene discussed is TP53; the disease is acute myeloid leukemia.